脆弱和瘤学:一个越来越常见的组合
Yanira Hernández-Aguiar1, Ángel Becerra-Bolaños1,2, Aurelio Rodríguez-Pérez1,2
1Department of Anesthesiology, Intensive Care and Pain Medicine, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain.
Cancer medicine
|December 26, 2025
概括
脆弱性显著影响癌症患者的预后和治疗耐受性. 评估脆弱性可以实现个性化瘤治疗,改善癌症老年人的治疗结果并降低癌症治疗风险.
科学领域:
- 老年医学 老年医学
- 在瘤学瘤学.
- 临床药理学 临床药理学
背景情况:
- 脆弱性,以减少生理储备为特征,在癌症患者中非常普遍.
- 它与更糟糕的预后,增加的发病率和治疗毒性有关.
- 了解虚弱与癌症的相互作用对于优化治疗决策至关重要.
研究的目的:
- 为了阐明脆弱和癌症之间的复杂关系.
- 为指导在瘤学中优化治疗决策.
- 提高脆弱癌症患者以患者为中心的治疗结果.
主要方法:
- 使用PubMed进行了一项叙事文献审查,该文献使用了2025年7月的时间.
- 搜索术语包括"脆弱"",瘤学"",癌症"",诊断"",治疗"和"预后".
- 优先考虑的临床指南,评论,观察性研究和随机试验.
主要成果:
- 脆弱性独立预测不良结果,包括术后发病率,化疗毒性,功能衰退和死亡率.
- 脆弱性评估是个性化瘤学的关键,使治疗个性化超越瘤类型.
- 多模式干预和瘤老年学模型改善耐受性,生活质量和遵守治疗计划.
结论:
- 虚弱是一个关键的临床因素,而不是癌症治疗的禁忌.
- 结构化的脆弱性评估和综合护理途径对于公平的患者管理至关重要.
- 将脆弱性整合到瘤学中,通过专注于整个患者,使个性化医疗变得更有效.
相关概念视频
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Drug Dosing: Geriatric Patients
199
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
199
Pharmacodynamics in Geriatric Patients: Effects of Age
172
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
172
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
176
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
176


